2014
DOI: 10.1186/1758-5996-6-35
|View full text |Cite
|
Sign up to set email alerts
|

Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE)

Abstract: BackgroundSitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently used to achieve glycemic targets in patients with type 2 diabetes mellitus (T2DM). The addition of DPP-4 inhibitors to ongoing insulin therapy is expected to reduce insulin dosage, leading to a reduction in the frequency of hypoglycaemia and/or weight gain. Recent studies have demonstrated potential anti-atherosclerotic effects for DPP-4 inhibitors. The aim of the present ongoing study is to assess the effects of sitagliptin on the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
25
0

Year Published

2015
2015
2017
2017

Publication Types

Select...
7

Relationship

5
2

Authors

Journals

citations
Cited by 17 publications
(25 citation statements)
references
References 50 publications
0
25
0
Order By: Relevance
“…Ultrasonographic scans of the carotid artery were performed by expert sonographers who were specifically trained to perform the prescribed study examination, as reported previously (16). To avoid intersonographer variability, each participant was examined by the same sonographer with the same equipment (high-resolution B-mode ultrasound scanner equipped with a high-frequency [.7.5-MHz] linear transducer, with a limit of detection of ,0.1 mm) throughout all the visits.…”
Section: Measurement Of Carotid Imtmentioning
confidence: 99%
See 2 more Smart Citations
“…Ultrasonographic scans of the carotid artery were performed by expert sonographers who were specifically trained to perform the prescribed study examination, as reported previously (16). To avoid intersonographer variability, each participant was examined by the same sonographer with the same equipment (high-resolution B-mode ultrasound scanner equipped with a high-frequency [.7.5-MHz] linear transducer, with a limit of detection of ,0.1 mm) throughout all the visits.…”
Section: Measurement Of Carotid Imtmentioning
confidence: 99%
“…Japanese patients with T2DM who regularly attended the outpatient diabetes clinics at 12 institutions in Japan were asked to participate in this study, as previously described in detail (16). Patients with T2DM in whom the target of blood glucose control specified in the Treatment Guide for Diabetes in 2010 (edited by the Japan Diabetes Society) (17) was not achieved despite insulin therapy, in addition to dietary/exercise therapy or concomitant therapeutic drugs for T2DM (other than DPP-4 inhibitors) over a period of $3 months, were included in the study.…”
Section: Study Populationmentioning
confidence: 99%
See 1 more Smart Citation
“…We reported recently that treatment with sitagliptin, a dipeptidyl peptidase‐4 inhibitor, attenuated the progression of carotid IMT in insulin‐treated patients with type 2 diabetes mellitus compared with conventional therapy1. Here, we compared the efficacy of treatment with sitagliptin with that of other modalities on the progression of carotid IMT in prespecified subgroups of the Sitagliptin Preventive Study of Intima‐Media Thickness Evaluation (SPIKE) registered on the University Hospital Medical Information Network Clinical Trials Registry (UMIN000007396)1, 2. The aim of the comparison was to identify the characteristics of patients who benefited most from the sitagliptin treatment in terms of decrease in IMT.…”
mentioning
confidence: 99%
“…After the exclusion of eight patients, data of 137 patients of the sitagliptin group and 137 of the conventional treatment group were subjected to analysis. The mean‐IMT of the common carotid arteries (mean‐IMT‐CCA) and right and left max‐IMT‐CCA were measured by expert sonographers at the start of the study, and the procedure was repeated after 52 and 104 weeks, as reported previously1, 2. Figure 1 shows differences in treatment‐induced delta change in carotid IMT, relative to baseline in 243 patients whose IMT data were available at baseline and 104 weeks, according to various predefined risk factors for atherosclerosis.…”
mentioning
confidence: 99%